<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of Clinical and Experimental Neurology</journal-id><journal-title-group><journal-title xml:lang="en">Annals of Clinical and Experimental Neurology</journal-title><trans-title-group xml:lang="ru"><trans-title>Анналы клинической и экспериментальной неврологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-5473</issn><issn publication-format="electronic">2409-2533</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">485</article-id><article-id pub-id-type="doi">10.17816/ACEN.2017.3.4</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Unknown</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The change in androgenic status in men with atherothrombotic stroke</article-title><trans-title-group xml:lang="ru"><trans-title>Изменение андрогенного статуса у мужчин c атеротромботическим инсультом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7682-6672</contrib-id><name-alternatives><name xml:lang="en"><surname>Maksimova</surname><given-names>Marina Yu.</given-names></name><name xml:lang="ru"><surname>Максимова</surname><given-names>Марина Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med), Prof., Head, 2nd Neurology department</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, руководитель 2-го неврологического отделения</p></bio><email>ncnmaximova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Moskvicheva</surname><given-names>Aleksandra S.</given-names></name><name xml:lang="ru"><surname>Москвичева</surname><given-names>Александра Станиславовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ncnmaximova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8726-8928</contrib-id><name-alternatives><name xml:lang="en"><surname>Chechetkin</surname><given-names>Andrey O.</given-names></name><name xml:lang="ru"><surname>Чечёткин</surname><given-names>Андрей Олегович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Head, Ultrasound diagnostic laboratory</p></bio><bio xml:lang="ru"><p>д.м.н., зав. лаб. ультразвуковых методов исследования</p></bio><email>ncnmaximova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Center of Neurology</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научный центр неврологии»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-09-28" publication-format="electronic"><day>28</day><month>09</month><year>2017</year></pub-date><volume>11</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>29</fpage><lpage>34</lpage><history><date date-type="received" iso-8601-date="2017-09-28"><day>28</day><month>09</month><year>2017</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Maksimova M.Y., Moskvicheva A.S., Chechetkin A.O.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, Maksimova M.Y., Moskvicheva A.S., Chechetkin A.O.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Maksimova M.Y., Moskvicheva A.S., Chechetkin A.O.</copyright-holder><copyright-holder xml:lang="ru">Maksimova M.Y., Moskvicheva A.S., Chechetkin A.O.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://annaly-nevrologii.com/pathID/article/view/485">https://annaly-nevrologii.com/pathID/article/view/485</self-uri><abstract xml:lang="en"><p><bold>Introduction. </bold>Last years special attention is paid to the age-related and gender aspects of pathogenesis of cerebrovascular disease.</p> <p><bold>Objective. </bold>To investigate the androgenic status in men with atherothrombotic stroke.</p> <p><bold>Materials and methods. </bold>There were 25 man, involved in our study (mean age 53 [45; 57]) with atherothrombotic stroke in carotid system, who were observed for the initial 48 hours since the development of neurological symptoms. The laboratory study included the estimation of blood lipid profile, carbohydrate metabolism and androginic status beside the general blood analysis and clinical urine examination. The level of free testosterone was determined by the calculation method using a nomogram according to Vermeulen (normal range 225 pmol/l or more). The levels of luteinizing hormone (normal range 2,5–11,0 U/l) (for exclusion primary hypogonadizme), the levels of testosterone (normal range 11,0–33,3 nM) and estradiol (normal range 73-206 pmol/l) were determined on an automatic chemiluminescent analyzer. Hypogonadizme was diagnosed by the level of total testosterone &lt;12 nM or the level of free testosterone &lt;225 pmol/l. The 14 patients (mean age 55 [49; 59]) with a chronical cerebrovascular insufficiency and without laboratory signs of lipid storage disease and carbohydrate metabolism disorder or age-related hypogonadizme composed a comparison group.</p> <p><bold>Results. </bold>The laboratory signs of androgen deficiency were detected by 72% patients with atherothrombotic stroke. Correlation link was established between androgenic deficit (total testosterone not less than 12 nM), diabetes mellitus type II (r=0.514, р=0.008) and alcohol overuse (r=0.535, р=0.033). A negative correlation relationship was established between the level of free testosterone and the body-weight index (r=–0.442, р=0.022). The lowest levels of total and free testosterone, Ме 7.2 [4.2; 9.8] nM and 135 [59; 181] pmol/l respectively, were observed in a group of patients with a combination of atherothrombotic stroke and metabolic syndrome. There was no statistically significant correlation of acquired hypogonadism and blood lipid levels.</p> <p><bold>Conclusion. </bold>The laboratory signs of acquired androgenic deficit were revealed in 72% of men (mean age 53.0 [45; 57]) with atherothrombotic stroke. The lowest values of total and free testosterone were observed in patients with the syndrome of multiple metabolic disorders.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold>В последние годы особое внимание привлекают возрастные и гендерные аспекты патогенеза нарушений мозгового кровообращения.</p> <p><bold>Цель исследования</bold>– изучение андрогенного статуса у мужчин с атеротромботическим инсультом.</p> <p><bold>Материалы и методы.</bold>В исследование включено 25 мужчин (средний возраст53 [45; 57])с атеротромботическим инсультом в бассейне артерий каротидной системы, поступивших в первые 48 ч с момента развития неврологической симптоматики. Лабораторное исследование наряду с общеклиническими анализами крови и мочи включало определение показателей липидного, углеводного обмена и андрогенного статуса. Уровень свободного тестостерона определялся расчетным методом с использованием номограммы поVermeulen(норма 225 пмоль/л или более). Уровни лютеинизирующего гормона (норма 2,5–11,0 ЕД/л) (для исключения первичного гипогонадизма), тестостерона (норма 11,0–33,3 нмоль/л) и эстрадиола (норма 73–206 пмоль/л) определялись на автоматическом хемилюминесцентном анализаторе «Vitros» («JohnsonandJohnson», Великобритания). Гипогонадизм диагностировался при уровне общего тестостерона менее 12 нмоль/л или свободного тестостерона менее 225 пмоль/л. Группу сравнения составили 14 пациентов (средний возраст Ме55 [49; 59])с хронической сосудисто-мозговой недостаточностью без лабораторных признаков нарушений липидного и углеводного обмена и возрастного гипогонадизма.</p> <p><bold>Результаты.</bold>Лабораторные признаки андрогенного дефицита выявлены у 72% пациентов с атеротромботическим инсультом. Установлена корреляционная связь андрогенного дефицита (общий тестостерон менее 12 нмоль/л) с сахарным диабетом 2-го типа (r=0,514, р=0,008) и злоупотреблением алкоголем (r=0,535, р=0,033). Установлена отрицательная корреляционная взаимосвязь между уровнем свободного тестостерона и индексом массы тела (r=–0,442, р=0,022). Наиболее низкие показатели общего и свободного тестостерона, Ме 7,2 [4,2; 9,8] нмоль/л и 135 [59; 181] пмоль/л соответственно, отмечались в группе больных с сочетанием атеротромботического инсульта и метаболического синдрома. Статистически значимой корреляции приобретенного гипогонадизма с уровнем липидов крови не выявлено.</p> <p><bold>Заключение.</bold>У мужчин (средний возраст Ме53,0 [45; 57])с атеротромботическим инсультом лабораторные признаки приобретенного дефицита андрогенов выявлены в 72%, при этом наиболее низкие показатели общего и свободного тестостерона наблюдались при наличии у пациентов синдрома множественных метаболических нарушений.</p></trans-abstract><kwd-group xml:lang="en"><kwd>atherothrombotic stroke, total and free testosterone</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>атеротромботический инсульт, общий и свободный тестостерон</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Demograficheskiy ezhegodnik Rossii. [Demographic Yearbook of Russia]. Moscow: 2015. (In Russ.)</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Skvortsova V.I. Rossiyskaya meditsina – primer dlya VOZ. [Russian medicine is an example for WHO]. Interview in «Nezavisimaya gazeta» 17.05.2017. (In Russ.)</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Suslina Z.A., Gulevskaya T.S., Maksimova M.Yu. et al. Narusheniya mozgovogokrovoobrashcheniya: diagnostika, lechenie, profilaktika. [Cerebrovascular disorders: diagnosis, treatment, prevention]. Moscow: MEDpress-inform, 2016. (In Russ.)</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>EUGenMed Cardiovascular Clinical Study Group, Regitz-Zagrosek V., Oertelt-Prigione S., Prescott E. et al. Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. Eur Heart J. 2016; 37 (1): 24–34. doi: 10.1093/eurheartj/ehv598. PMID: 26530104.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Yamatani H., Takahashi K., Nagase S. Sex hormones and physiological function. Nihon Rinsho.2015; 73(4): 565–70. PMID: 25936142.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Pappa T., Vemmos K., Mantzou E. et al. Estradiol levels predict short-term adverse health outcomes in postmenopausal acute stroke women. Eur J Neurol. 2012; 19(10): 1300–4. doi: 10.1111/j.1468-1331.2012.03714.x. PMID: 22509950.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>dos Santos R.L., da Silva F.B., Ribeiro R.F. Jr. et al. Sex hormones in the cardiovascular system.Horm Mol Biol Clin Investig. 2014; 18(2): 89–103. doi: 10.1515/hmbci-2013-0048.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Ranthe M.F., Andersen E.A., Wohlfahrt J. et al. Pregnancy loss and later risk of atherosclerotic disease. Circulation. 2013; 127(17): 1775–82. doi: 10.1161/CIRCULATIONAHA.112.000285. PMID: 23536362.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Ostchega Y., Dillon C.F., Hughes J.P. et al. Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc. 2007; 55(7): 1056–65. PMID: 17608879.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Holmegard H.N., Nordestgaard B.G., Jensen G.B. et al. Sex Hormones and ischemic stroke: A prospective cohort study and meta-analyses. J Clin Endocrinol Metab. 2016; 101(1): 69–78. doi: 10.1210/jc.2015-2687. PMID: 26509870.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Dehlendorff C., Andersen K.K., Olsen T.S. Sex disparities in stroke: women have more severe strokes but better survival than men. J Am Heart Assoc. 2015; 4(7): e001967. doi: 10.1161/JAHA.115.001967. PMID: 26150479.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Smith G.N. The maternal health clinic: improving women's cardiovascular health. Semin perinatol. 2015; 39(4): 316–9. doi: 10.1053/j.semperi.2015.05.012. Review.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Kloner R.A., Carson C. 3rd, Dobs A. et al. Testosterone and cardiovascular disease. J Am Coll Cardiol. 2016; 67(5): 545–57. doi: 10.1016/j.jacc.2015.12.005. Review. PMID: 26846952.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Lunenfeld B. 20 years since the International Society of the Ageing Male (ISSAM) was founded. Aging Male. 2016; 19(4): 259–275. PMID: 27879154.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Morley J.E. The diagnosis of late life hypogonadism. Aging Male. 2007; 10(4): 217–20. Review. PMID: 18033631.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Muller M., van den Beld A.W., Bots M.L., et al. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation. 2004; 109(17): 2074–9. PMID: 15096452.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Svartberg J., Jenssen T., Sundsfjord J. et al. The associations of endogenous testosterone and sex hormone-binding globulin with glycosylated hemoglobin levels, in community dwelling men. The Tromsø Study. Diabetes Metab. 2004; 30(1): 29–34. PMID: 15029095.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Yeap B.B., Hyde Z., Almeida O.P. et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab. 2009; 94(7): 2353–9. doi: 10.1210/jc.2008-2416. PMID: 19351733.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Kim C., Cushman M., Kleindorfer D. et al. A review of the relationships between endogenous sex steroids and incident ischemic stroke and coronary heart disease events. Curr Cardiol Rev. 2015; 11(3): 252–60. PMID: 25563292.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Reeves M.J., Bushnell C.D., Howard G. et al. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet neurology. 2008; 7: 915–26. PMID: 18722812 DOI: 10.1016/S1474-4422(08)70193-5.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Appelros P., Stegmayr B., Terént A. Sex differences in stroke epidemiology: a systematic review.Stroke. 2009; 40: 1082–90. doi:10.1161/STROKEAHA.108.540781.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Wang Y., Rudd A.G., Wolfe C.D. Age and Ethnic Disparities in Incidence of Stroke Over Time: The South London Stroke Register. Stroke. 2013; 44(12): 3298–304. doi: 10.1161/STROKEAHA.113.002604.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Kapoor D., Jones T.H. Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention? Drugs &amp; aging. 2008; 25: 357–69. PMID: 18447401.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Kupelian V., Hayes F.J., Link C.L. et al. Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic groups. The Journal of clinical endocrinology and metabolism. 2008; 93: 3403–10. PMID: 18559915 DOI: 10.1210/jc.2008-0054.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Shores M.M., Smith N.L., Forsberg C.W. et al. Testosterone treatment and mortality in men with low testosterone levels. The Journal of clinical endocrinology and metabolism. 2012; 97: 2050–8. PMID: 22496507 DOI: 10.1210/jc.2011-2591.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Spitzer M., Huang G., Basaria S. et al. Risks and benefits of testosterone therapy in older men. Nature reviews Endocrinology. 2013; 9: 414–24. PMID: 23591366 DOI: 10.1038/nrendo.2013.73.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Quillinan N., Deng G., Grewal H. et al. Androgens and stroke: good, bad or indifferent? Exp Neurol. 2014; 259: 10–5. doi: 10.1016/j.expneurol.2014.02.004.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Ohlsson C., Barrett-Connor E., Bhasin S. et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J. Am. Coll. Cardiol. 2011; 58(16): 1674–1681. doi: 10.1016/j.jacc.2011.07.019.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Soisson V., Brailly-Tabard S., Helmer C. et al. A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort study. Maturitas. 2013; 75(3): 282–288. doi: 10.1016/j.maturitas.2013.04.012.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Ruige J.B., Mahmoud A.M., De Bacquer D. et al. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart. 2011; 97(11): 870–875. doi: 10.1136/hrt.2010.210757.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Haring R., Teng Z., Xanthakis V. et al. Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and all-cause mortality in elderly men from the Framingham Heart Study. Clin. Endocrinol. (Oxf) 2013; 78(4): 629–634. doi: 10.1111/cen.12013.</mixed-citation></ref></ref-list></back></article>
